May 23, 2022 6:00am EDT Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
Apr 20, 2022 6:10am EDT Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
Apr 19, 2022 6:21am EDT Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
Mar 03, 2022 9:19am EST Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
Feb 01, 2022 6:00am EST Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Jan 24, 2022 6:00am EST Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
Dec 15, 2021 6:00am EST Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
Dec 09, 2021 6:29am EST Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology